[1] |
KASER A,ZEISSIG S,BLUMBERG R S.Inflammatory bowel disease[J]. Annu Rev Immunol,2010,28:573-621.
|
[2] |
OUYANG Q,XUE L Y.Inflammatory bowel disease in the 21(st) century in China:turning challenges into opportunities[J]. J Dig Dis,2012,13(4):195-199.
|
[3] |
OOI C J,MAKHARIA G K,HILMI I,et al.Asia Pacific Consensus Statements on Crohn's disease. Part 1:Definition,diagnosis,and epidemiology:(Asia Pacific Crohn's Disease Consensus-Part 1)[J]. J Gastroenterol Hepatol,2016,31(1):45-55.
|
[4] |
SAVIGE J,DIMECH W,FRITZLER M,et al.Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines,comments,and recommendations for testing in other autoimmune diseases[J]. Am J Clin Pathol,2003,120(3):312-318.
|
[5] |
SAXON A,SHANAHAN F,LANDERS C,et al.A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease[J]. J Allergy Clin Immunol,1990,86(2):202-210.
|
[6] |
KYRIAKIDI K S,TSIANOS V E,KARVOUNIS E,et al.Neutrophil anti-neutrophil cytoplasmic autoantibody proteins:bactericidal increasing protein,lactoferrin,cathepsin,and elastase as serological markers of inflammatory bowel and other diseases[J]. Ann Gastroenterol,2016,29(3):258-267.
|
[7] |
BASSO D,ZAMBON C F,PLEBANI M.Inflammatory bowel diseases:from pathogenesis to laboratory testing[J]. Clin Chem Lab Med,2014,52(4):471-481.
|
[8] |
TAKAISHI H,KANAI T,NAKAZAWA A,et al.Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins(HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies(ASCA):accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype[J]. J Gastroenterol,2012,47(9):969-977.
|
[9] |
SOBAJIMA J,OZAKI S,OSAKADA F,et al.Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies(P-ANCA) in ulcerative colitis:non-histone chromosomal proteins,HMG1 and HMG2[J]. Clin Exp Immunol,1997,107(1):135-140.
|
[10] |
STÖCKER W,OTTE M,ULRICH S,et al. Autoimmunity to pancreatic juice in Crohn's disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease[J]. Scand J Gastroenterol Suppl,1987,139:41-52.
|
[11] |
KOMOROWSKI L,TEEGEN B,PROBST C,et al.Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens:the glycoproteins CUZD1 and GP2[J]. J Crohns Colitis,2013,7(10):780-790.
|
[12] |
BONNEAU J,DUMESTRE-PERARD C,RINAUDO-GAUJOUS M,et al.Systematic review:new serological markers(anti-glycan,anti-GP2,anti-GM-CSF Ab) in the prediction of IBD patient outcomes[J]. Autoimmun Rev,2015,14(3):231-245.
|
[13] |
DENG C,LI W,LI J,et al.Diagnostic value of the antiglycoprotein-2 antibody for Crohn's disease:a PRISMA-compliant systematic review and meta-analysis[J]. BMJ Open,2017,7(6):e014843.
|
[14] |
WERNER L,PACLIK D,FRITZ C,et al.Identification of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses[J]. J Immunol,2012,189(6):2774-2783.
|
[15] |
LIASKOS C,RIGOPOULOU E I,ORFANIDOU T,et al.CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases[J]. Clin Dev Immunol,2013,2013:968041.
|
[16] |
CONRAD K,ROGGENBUCK D,LAASS M W.Diagnosis and classification of ulcerative colitis[J]. Autoimmun Rev,2014,13(4-5):463-466.
|
[17] |
LAWRANCE I C,HALL A,LEONG R,et al.A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD[J]. Inflamm Bowel Dis,2005,11(10):890-897.
|
[18] |
DÄBRITZ J. Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease[J]. Am J Physiol Gastrointest Liver Physiol,2014,306(6):G455-G465.
|
[19] |
EGEA L,MCALLISTER C S,LAKHDARI O,et al.GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa[J]. J Immunol,2013,190(4):1702-1713.
|
[20] |
HERSZÉNYI L,TULASSAY Z. The role of autoantibodies in inflammatory bowel disease[J]. Dig Dis,2012,30(2):201-207.
|
[21] |
RIEDER F,SCHLEDER S,WOLF A,et al.Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior[J]. Inflamm Bowel Dis,2010,16(2):263-274.
|
[22] |
PRIDEAUX L,DE CRUZ P,NG S C,et al.Serological antibodies in inflammatory bowel disease:a systematic review[J]. Inflamm Bowel Dis,2012,18(7):1340-1355.
|
[23] |
PAPP M,LAKATOS P L.Serological studies in inflammatory bowel disease:how important are they?[J]. Curr Opin Gastroenterol,2014,30(4):359-364.
|
[24] |
PAUL S,BOSCHETTI G,RINAUDO-GAUJOUS M,et al.Association of anti-glycan antibodies and inflammatory bowel disease course[J]. J Crohns Colitis,2015,9(6):445-451.
|
[25] |
ZHOU G,SONG Y,YANG W,et al.ASCA,ANCA,ALCA and many more:are they useful in the diagnosis of inflammatory bowel disease?[J]. Dig Dis,2016,34(1-2):90-97.
|
[26] |
SPIVAK J,LANDERS C J,VASILIAUSKAS E A,et al.Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease[J]. Inflamm Bowel Dis,2006,12(12):1122-1130.
|
[27] |
WANG Z Z,SHI K,PENG J.Serologic testing of a panel of five antibodies in inflammatory bowel diseases:diagnostic value and correlation with disease phenotype[J]. Biomed Rep,2017,6(4):401-410.
|
[28] |
CHIODINI R J.Crohn's disease and the mycobacterioses:a review and comparison of two disease entities[J]. Clin Microbiol Rev,1989,2(1):90-117.
|
[29] |
ZAMANI S,ZALI M R,AGHDAEI H A,et al.Mycobacterium avium subsp. paratuberculosis and associated risk factors for inflammatory bowel disease in Iranian patients[J]. Gut Pathog,2017,9:1.
|
[30] |
ONO Y,KANMURA S,MORINAGA Y,et al.The utility of apoptosis inhibitor of macrophages as a possible diagnostic marker in patients with Crohn's disease[J]. BMC Gastroenterol,2017,17(1):40.
|
[31] |
YAMAGUCHI Y,NODA H,OKANIWA N,et al.Serum-derived hyaluronan-associated protein is a novel biomarker for inflammatory bowel diseases[J]. Digestion,2017,95(2):146-155.
|